Core‐binding factor acute myeloid leukemia with t(8;21): Risk factors and a novel scoring system (I‐CBFit)
Sign Up to like & getrecommendations! Published in 2018 at "Cancer Medicine"
DOI: 10.1002/cam4.1733
Abstract: Although the prognosis of core‐binding factor (CBF) acute myeloid leukemia (AML) is better than other subtypes of AML, 30% of patients still relapse and may require allogeneic hematopoietic cell transplantation (alloHCT). However, there is no… read more here.
Keywords: binding factor; scoring system; myeloid leukemia; core binding ... See more keywords
Characterization of open chromatin sensitive to actin polymerization and identification of core‐binding factor subunit beta as mechanosensitive nucleocytoplasmic shuttling protein
Sign Up to like & getrecommendations! Published in 2024 at "Cytoskeleton"
DOI: 10.1002/cm.21925
Abstract: Mechanotransduction leads to a variety of biological responses including gene expression, changes in cell shape, migration, tissue development, and immune responses. Dysregulation of mechanotransduction is implicated in the progression of various diseases such as cardiovascular… read more here.
Keywords: mechanosensitive nucleocytoplasmic; open chromatin; nucleocytoplasmic shuttling; core binding ... See more keywords
Hypomethylating agent monotherapy in core binding factor acute myeloid leukemia: a French multicentric retrospective study
Sign Up to like & getrecommendations! Published in 2024 at "Annals of Hematology"
DOI: 10.1007/s00277-024-05623-0
Abstract: Very few data are available about hypomethylating agent (HMA) efficiency in core binding factor acute myeloid leukemias (CBF-AML). Our main objective was to evaluate the efficacy and safety of HMA in the specific subset of… read more here.
Keywords: hypomethylating agent; core binding; cbf; cbf aml ... See more keywords
Response kinetics and factors predicting survival in core-binding factor leukemia
Sign Up to like & getrecommendations! Published in 2018 at "Leukemia"
DOI: 10.1038/s41375-018-0158-1
Abstract: Core-binding factor (CBF) acute myeloid leukemia (AML) is characterized by t(8;21)(q22;q22) and inv(16)(p13;q22)/t (16;16)(p13;q22) abnormalities, and despite mutational and cytogenetic heterogeneity among t(8;21) and inv(16), these entities share similarities in prognosis, are grouped together, and… read more here.
Keywords: regression; response; flag; core binding ... See more keywords
Residual normal B-cell profiles in monoclonal B-cell lymphocytosis versus chronic lymphocytic leukemia
Sign Up to like & getrecommendations! Published in 2018 at "Leukemia"
DOI: 10.1038/s41375-018-0164-3
Abstract: Minimal residual core binding factor AMLs by real time quantitative PCR—initial response to chemotherapy predicts event free survival and close monitoring of peripheral blood unravels the kinetics of relapse. Leuk Res. 2006;30:389–95. 8. Weisser M,… read more here.
Keywords: cell; minimal residual; binding factor; core binding ... See more keywords
Core binding factor acute myelogenous leukemia-2021 treatment algorithm
Sign Up to like & getrecommendations! Published in 2021 at "Blood Cancer Journal"
DOI: 10.1038/s41408-021-00503-6
Abstract: Core binding factor acute myelogenous leukemia (CBF-AML), characterized by the presence of either t(8;21) (q22;q22) or inv(16) (p13q22)/t(16;16), is considered good-risk AML in the context of cytarabine based intensive chemotherapy. Still, outcome can be improved… read more here.
Keywords: factor acute; binding factor; myelogenous leukemia; core binding ... See more keywords
Is the revised International staging system for myeloma valid in a real world population?
Sign Up to like & getrecommendations! Published in 2018 at "British Journal of Haematology"
DOI: 10.1111/bjh.14341
Abstract: Larson, R.A. & Bloomfield, C.D. (2005) Prognostic factors and outcome of core binding factor acute myeloid leukemia patients with t(8;21) differ from those of patients with inv(16): a Cancer and Leukemia Group B Study. Journal… read more here.
Keywords: myeloid leukemia; oncology; core binding; acute myeloid ... See more keywords
Minimal Residual Disease Eradication by Azacitidine Maintenance in a Patient with Core-Binding Factor Acute Myeloid Leukemia
Sign Up to like & getrecommendations! Published in 2020 at "Chemotherapy"
DOI: 10.1159/000512314
Abstract: Although core-binding factor AML (CBF-AML) has a favorable outcome, disease relapses occur in up to 35% of patients. Minimal residual disease (MRD) monitoring is one of the important tools to enable us to identify patients… read more here.
Keywords: binding factor; minimal residual; maintenance; disease ... See more keywords
Predictors of Survival in Core Binding Factor Acute Myeloid Leukemia: An Analysis of the National Cancer Database
Sign Up to like & getrecommendations! Published in 2024 at "Blood"
DOI: 10.1182/blood-2024-194100
Abstract: Background Core binding factor acute myeloid leukemia (CBF AML) is characterized by t(8;21) or inv(16). Though characterized as favorable risk due to high remission rates after cytarabine-based chemotherapy, prior population-based studies have found significantly lower… read more here.
Keywords: treatment; survival; core binding; analysis ... See more keywords
Core binding factor leukemia hijacks T-cell prone PU.1 antisense promoter.
Sign Up to like & getrecommendations! Published in 2021 at "Blood"
DOI: 10.1182/blood.2020008971
Abstract: The blood system serves as a key model for cell differentiation and cancer. It is orchestrated by precise spatiotemporal expression of crucial transcription factors. One of the key master regulators in the hematopoietic systems is… read more here.
Keywords: transcription; binding factor; antisense promoter; core binding ... See more keywords
Combination of dasatinib with chemotherapy in previously untreated core binding factor acute myeloid leukemia: CALGB 10801.
Sign Up to like & getrecommendations! Published in 2020 at "Blood advances"
DOI: 10.1182/bloodadvances.2019000492
Abstract: Acute myeloid leukemia (AML) with either t(8;21)(q22;q22) or inv(16)(p13q22)/t(16;16)(p13;q22) is referred to as core binding factor (CBF) AML. Although categorized as favorable risk, long-term survival for these patients is only ∼50% to 60%. Mutated (mut)… read more here.
Keywords: myeloid leukemia; calgb 10801; core binding; acute myeloid ... See more keywords